RM Partners, as part of the Cancer Vanguard, has worked in collaboration with the charities Breast Cancer Care and Breast Cancer Now to develop a national patient information leaflet ‘Trastuzumab Biosimilars’. This information is designed for breast cancer patients who are being treated with trastuzumab intravenously. It explains what biosimilars are and how they work. It is available for download below and will also available for patients on the breast cancer charity websites.

A generic patient letter has also been produced, to accompany the patient information leaflet and inform patients of the switch to biosimilar trastuzumab.

These resources, in conjunction with the existing generic biosimilar resource material, can help to support the early adoption of biosimilar trastuzumab in your Trust.